OS THERAPIES INCORPORATED

NYSE: OSTX (OS Therapies Incorporated)

Kemas kini terakhir: 5 hari lalu, 10:34PM

1.20

-0.06 (-4.76%)

  • 1H -4.76%
  • 5H -9.77%
  • 1B -17.81%
  • 6B -44.95%
  • Tahun Ke Tarikh -10.45%
  • 1T -39.09%
  • 5T -52.19%
Penutupan Terdahulu 1.26
Buka 1.25
Jumlah Dagangan 812,953
Purata Dagangan (3B) 538,970
Modal Pasaran 42,257,224
Harga / Buku (P/B) 13.46
Julat 52 Minggu
1.12 (-6%) — 2.98 (148%)
Tarikh Pendapatan 17 Nov 2025
EPS Cair (TTM) -0.990
Nisbah Semasa (MRQ) 1.16
Aliran Tunai Operasi (OCF TTM) -10.08 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -12.28 M
Pulangan Atas Aset (ROA TTM) -263.81%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok OS Therapies Incorporated - -

AISkor Stockmoo

0.6
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam NA
Volatiliti Harga 3.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -2.5
Purata 0.63

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
OSTX 42 M - - 13.46
LCTX 387 M - - 17.45
CYBN 359 M - - 2.70
PLX 235 M - 32.44 4.10
ARMP 233 M - - 2.11
IBIO 45 M - - 1.32

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 33.38%
% Dimiliki oleh Institusi 1.38%

Pemilikan

Nama Tarikh Syer Dipegang
Cm Management, Llc 31 Dec 2025 400,000
Mercer Global Advisors Inc /Adv 30 Sep 2025 20,440

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
04 Feb 2026 Pengumuman OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies
02 Feb 2026 Pengumuman OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
15 Jan 2026 Pengumuman OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
14 Jan 2026 Pengumuman OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
12 Jan 2026 Pengumuman OS Therapies Enters into Warrant Inducement Agreements
05 Jan 2026 Pengumuman OS Therapies Provides First Half 2026 Corporate Outlook
15 Dec 2025 Pengumuman OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
09 Dec 2025 Pengumuman OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
05 Dec 2025 Pengumuman OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
25 Nov 2025 Pengumuman OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
21 Nov 2025 Pengumuman Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25
20 Nov 2025 Pengumuman OS Therapies to Spinoff OS Animal Health into Standalone Public Company
17 Nov 2025 Pengumuman OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda